Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.
AuthorsBrookes, K E
Backen, Alison C
Ward, Timothy H
Jayson, Gordon C
AffiliationClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractBACKGROUND: Successful introduction of new anticancer agents into the clinic is often hampered by a lack of qualified biomarkers. Studies have been conducted of 17 ELISAs representing a potential panel of pharmacodynamic/predictive biomarkers for drugs targeted to tumour vasculature. METHODS: The fit-for-purpose approach to method validation was used. Stability studies were performed using recombinant proteins in surrogate matrices, endogenous analytes in healthy volunteer and cancer patient plasma. The impact of platelet depletion was investigated. RESULTS: Method validation focused on measuring precision and showed that 15 of the 17 assays were within acceptable limits. Stability at -80 degrees C was shown for 3 months with all recombinant proteins in surrogate matrices, whereas under the same conditions instability was observed with KGF in platelet-rich and platelet-depleted plasma, and with PDGF-BB in platelet-depleted plasma from cancer patients. For measurement of extracellular circulating analytes, platelet depletion should be conducted before freezing of plasma to prevent release of PDGF-BB, FGFb and VEGF-A. A protocol was developed to remove >90% platelets from plasma requiring centrifugation at 2000 g for 25 min. CONCLUSIONS: These studies highlight the need for assay validation and crucial assessment of sample handling issues before commencement of biomarker analysis in clinical trials.
CitationIssues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. 2010, 102 (10):1524-32 Br J Cancer
JournalBritish Journal of Cancer
- Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.
- Authors: Cummings J, Raynaud F, Jones L, Sugar R, Dive C
- Issue date: 2010 Oct 26
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
- Authors: Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C
- Issue date: 2006 Jul 3
- 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use.
- Authors: Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C
- Issue date: 2009 Mar 15
- A computational solution to improve biomarker reproducibility during long-term projects.
- Authors: Feng F, Thompson MP, Thomas BE, Duffy ER, Kim J, Kurosawa S, Tashjian JY, Wei Y, Andry C, Stearns-Kurosawa DJ
- Issue date: 2019
- Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
- Authors: Cummings J, Ranson M, Butt F, Moore D, Dive C
- Issue date: 2007 Nov